{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:00:46Z","timestamp":1773309646598,"version":"3.50.1"},"reference-count":297,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[1993,11,1]],"date-time":"1993-11-01T00:00:00Z","timestamp":752112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[1993,11]]},"DOI":"10.1016\/0006-3223(93)90044-e","type":"journal-article","created":{"date-parts":[[2003,4,24]],"date-time":"2003-04-24T17:37:29Z","timestamp":1051205849000},"page":"713-738","source":"Crossref","is-referenced-by-count":99,"title":["Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia"],"prefix":"10.1016","volume":"34","author":[{"given":"Robert","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Chouinard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/0006-3223(93)90044-E_BIB1","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/0006-3223(85)90006-X","article-title":"Tardive dyskinesia: relation to computer-tomographic, endocrine and psychophatological variables","volume":"20","author":"Albus","year":"1985","journal-title":"Biol Psychiatry"},{"issue":"2","key":"10.1016\/0006-3223(93)90044-E_BIB2","first-page":"5","article-title":"Tremorigraphic studies in tardive dyskinesia","volume":"12","author":"Alpert","year":"1976","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/0006-3223(93)90044-E_BIB3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF01245132","article-title":"Striatal binding of 11C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: no evidence for altered dopamine D2 receptor binding","volume":"79","author":"Andersson","year":"1990","journal-title":"J Neural Trans"},{"key":"10.1016\/0006-3223(93)90044-E_BIB4","series-title":"Abstract, 9th World Congress of Psychiatry","article-title":"Tardive dyskinesia: Sex- and age-specific prevelance rates by body area","author":"Annable","year":"1993"},{"key":"10.1016\/0006-3223(93)90044-E_BIB5","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/0140-6736(91)92076-E","article-title":"Is levodopa harmful?","volume":"338","author":"Arts","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/0006-3223(93)90044-E_BIB6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0014-2999(73)90028-9","article-title":"Tolerance phenomena with neuroleptics: catalepsy, apomorphine stereortypies and striatl dopamine metabolism in the cat after single and repeated administration of loxapine and haloperidol","volume":"22","author":"Asper","year":"1973","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1600-0773.1979.tb02369.x","article-title":"Pharmacological modification of experimental tardive dyskenesia","volume":"45","author":"Barany","year":"1979","journal-title":"Acta Pharmacol Toxicol (Coppen)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB8","first-page":"791","article-title":"L-DOPA therapy in Parkinson's disease. A critical review of nine years experience","volume":"101","author":"Barbeau","year":"1969","journal-title":"Can Med Assoc J"},{"key":"10.1016\/0006-3223(93)90044-E_BIB9","first-page":"301","article-title":"The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia","volume":"4","author":"Barnes","year":"1987","journal-title":"Psychiatr Dev"},{"key":"10.1016\/0006-3223(93)90044-E_BIB10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF00346087","article-title":"Computerized tomograpgy in tardive dyskinesia. Evidence of structural abnormalities in the basal ganglia system","volume":"233","author":"Bartels","year":"1983","journal-title":"Arch Psychiatr Nervenkr"},{"key":"10.1016\/0006-3223(93)90044-E_BIB11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ana.410310202","article-title":"Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illness?","volume":"31","author":"Beal","year":"1992","journal-title":"Ann Neurol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0006-8993(86)90783-3","article-title":"Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-Parkinsonian monkeys. Correlation with [3H] spiperone binding","volume":"379","author":"Bedard","year":"1986","journal-title":"Brain Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1017\/S0317167100041500","article-title":"Levodopa-induced dyskinesia; facts and fancy. What does the MPTP monkey model tell us?","volume":"19","author":"Bedard","year":"1992","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/0006-3223(93)90044-E_BIB14","first-page":"463","article-title":"Parkinson's disease and long-term levodopa therapy","volume":"45","author":"Bergmann","year":"1987","journal-title":"Adv Neurol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","article-title":"Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations","volume":"20","author":"Bernheimer","year":"1973","journal-title":"J Neurol Sci"},{"key":"10.1016\/0006-3223(93)90044-E_BIB16","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1600-0404.1974.tb02820.x","article-title":"Abnormal involuntary movements induced by anticholinergic therapy","volume":"50","author":"Birket-Smith","year":"1974","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/0006-3223(93)90044-E_BIB17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1600-0404.1975.tb05769.x","article-title":"Abnormal involuntary movements in relation to anticholinergic and levodopa therapy","volume":"52","author":"Birket-Smith","year":"1975","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/0006-3223(93)90044-E_BIB18","first-page":"28","article-title":"Coexistence of severe Parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy","volume":"45","author":"Bitton","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB19","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1136\/jnnp.52.11.1248","article-title":"Striatal dopamine receptors in tardive dyskinesia: PET study","volume":"52","author":"Blin","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB20","first-page":"213","article-title":"Risperidone: clinical safety and efficacy in schizophrenia","volume":"28","author":"Borison","year":"1992","journal-title":"Psychopharmacol Bull"},{"issue":"suppl 62","key":"10.1016\/0006-3223(93)90044-E_BIB21","article-title":"Morphology of the basal ganglia in Parkinson's disease","volume":"52","author":"Bottcher","year":"1975","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/0006-3223(93)90044-E_BIB22","first-page":"156","article-title":"Les dyskin\u00e9sies tardive des neuroleptiques. Complication majeur des traitements neuroleptiques au long cours","volume":"145","author":"Bourgeois","year":"1987","journal-title":"Ann Med Psychol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB23","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/00002826-199010000-00006","article-title":"Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys","volume":"13","author":"Boyce","year":"1990","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB24","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1212\/WNL.40.6.927","article-title":"Different effects of D1 and D2 agonists in MTPT-treated primates; functional implications for Parkinson's disease","volume":"40","author":"Boyce","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/0006-3223(93)90044-E_BIB25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF01244638","article-title":"Selective D-1 receptor agonist treatment of Parkinson's disease","volume":"68","author":"Braun","year":"1987","journal-title":"J Neural Transm"},{"key":"10.1016\/0006-3223(93)90044-E_BIB26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1192\/bjp.159.3.399","article-title":"The psychological consequences of tardive dyskinesia. The effect of drug-induced Parkinsonism and the topography of the dyskinetic movements","volume":"159","author":"Brown","year":"1991","journal-title":"Br J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB27","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000115172","article-title":"Loss of striatal neurons in Parkinson's disease. A cytometric study","volume":"19","author":"Bugiani","year":"1980","journal-title":"Eur Neurol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0021-9681(64)90075-X","article-title":"Discontinuation or reduction of chemotherapy in chronic schizophrenics","volume":"17","author":"Caffey","year":"1964","journal-title":"J Chronic Dis"},{"key":"10.1016\/0006-3223(93)90044-E_BIB29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000118196","article-title":"Treatment of mania using a calcium antagonist preliminary trial","volume":"14","author":"Caillard","year":"1985","journal-title":"Neuropsychobiology"},{"key":"10.1016\/0006-3223(93)90044-E_BIB30","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0024-3205(81)90677-9","article-title":"Tolerance to behavioral effects of haloperidol","volume":"29","author":"Campbell","year":"1981","journal-title":"Life Sci"},{"key":"10.1016\/0006-3223(93)90044-E_BIB31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/archpsyc.1985.01790290119020","article-title":"Prolonged pharmacologic activity of neuroleptics","volume":"42","author":"Campbell","year":"1985","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB32","series-title":"Chronic treatments in Neuropsychiatry","first-page":"15","article-title":"Tardive dyskinesia: epidemiological factors as a guide for prevention and management","volume":"Vol 40","author":"Casey","year":"1985"},{"key":"10.1016\/0006-3223(93)90044-E_BIB33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00426532","article-title":"Pharmacological characterization of tardive dyskinesia","volume":"54","author":"Casey","year":"1977","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB34","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1212\/WNL.41.5.622","article-title":"Early initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias or dementia in Parkinson's disease","volume":"41","author":"Cedarbaum","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/0006-3223(93)90044-E_BIB35","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/archneur.1973.00490290068008","article-title":"Levodopa-induced dyskinesias. Comparison in Parkinsonism-dementia and amyotrophic lateral sclerosis","volume":"29","author":"Chase","year":"1973","journal-title":"Arch Neurol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0920-9964(91)90050-2","article-title":"Severe cases of neuroleptic-induced supersensitivity psychosis, diagnostic criteria for the disorder and its treatment","volume":"5","author":"Chouinard","year":"1990","journal-title":"Schizophr Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB37","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1176\/ajp.135.11.1409","article-title":"Neuroleptic-induced supersensitivity psychosis","volume":"135","author":"Chouinard","year":"1978","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1176\/ajp.136.1.79","article-title":"Factors related to tardive dyskinesia","volume":"136","author":"Chouinard","year":"1979","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1176\/ajp.136.2.228","article-title":"Tardive dyskinesia and antiparkinsonian medication","volume":"136","author":"Chouinard","year":"1979","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB40","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1176\/ajp.136.10.1323","article-title":"Early onset of tardive dyskinesia: case report","volume":"136","author":"Chouinard","year":"1979","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1176\/ajp.137.1.16","article-title":"Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics","volume":"137","author":"Chouinard","year":"1980","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB42","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1176\/ajp.137.4.507a","article-title":"Sex differences and tardive dyskinesia","volume":"137","author":"Chouinard","year":"1980","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB43","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/ajp.139.3.360","article-title":"Reversible and irreversible tardive dyskinesia: a case report","volume":"139","author":"Chouinard","year":"1982","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB44","first-page":"849","article-title":"High neuroleptic plasma levels in patients manifesting supersensitivity psychosis","volume":"17","author":"Chouinard","year":"1982","journal-title":"Biol Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB45","first-page":"259","article-title":"A five-year follow-up study of tardive dyskinesia","volume":"22","author":"Chouinard","year":"1986","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/0006-3223(93)90044-E_BIB46","first-page":"891","article-title":"Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients","volume":"22","author":"Chouinard","year":"1986","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/0006-3223(93)90044-E_BIB47","first-page":"221","article-title":"Long-term effects of L-DOPA and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptons","volume":"23","author":"Chouinard","year":"1987","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/0006-3223(93)90044-E_BIB48","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1097\/00004714-198808001-00005","article-title":"A 5-year prospective longitudinal study of tardive dyskinesia: factor predicting appearance of new cases","volume":"8","author":"Chouinard","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB49","first-page":"337","article-title":"Treatment of neuroleptic-induced supersensitivity psychosis with antiepileptic drugs: report of a series of 43 cases","volume":"26","author":"Chouinard","year":"1990","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/0006-3223(93)90044-E_BIB50","doi-asserted-by":"crossref","first-page":"110A","DOI":"10.1016\/0006-3223(90)90231-P","article-title":"A ten-year follow-up of supersensitivity psychosis","volume":"27","author":"Chouinard","year":"1990","journal-title":"Biol Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB51","series-title":"Syllabus and proceedings of the 143rd Annual Meeting of the American Psychiatric Association","first-page":"62","article-title":"Factors affecting the course of tardive dyskinesia: a ten-year follow-up","author":"Chouinard","year":"1990"},{"key":"10.1016\/0006-3223(93)90044-E_BIB52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients","volume":"13","author":"Chouinard","year":"1993","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB53","first-page":"130A","article-title":"Risperidone and clozapine in the treatment of neuroleptic-induced supersensitivity psychosis","volume":"33","author":"Chouinard","year":"1993","journal-title":"Biol Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0447.1970.tb02097.x","article-title":"Neuropathological investigation of 28 brains from patients with dyskinesia","volume":"46","author":"Christensen","year":"1970","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/0006-3223(93)90044-E_BIB55","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00004714-198712000-00002","article-title":"The risks and benefits of clozapine versus chlorpromazine","volume":"7","author":"Claghorn","year":"1987","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB56","first-page":"35","article-title":"Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"358","author":"Clarke","year":"1988","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB57","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1476-5381.1985.tb08863.x","article-title":"Failure of SKF 38393-A to relieve Parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset","volume":"85","author":"Close","year":"1985","journal-title":"Br J Pharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB58","doi-asserted-by":"crossref","first-page":"141S","DOI":"10.1016\/0197-0186(92)90227-I","article-title":"SCH 39166, a potential antipsychotic drug, does not evoke movement disorders in Cebus monkeys","volume":"20","author":"Coffin","year":"1992","journal-title":"Neurochem Int"},{"key":"10.1016\/0006-3223(93)90044-E_BIB59","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/archpsyc.1988.01800330113019","article-title":"Persistence of haloperidol in the brain","volume":"45","author":"Cohen","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB60","first-page":"269","article-title":"Clozapine efficacy in schizophrenic nonresponders","volume":"24","author":"Conley","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/0006-3223(93)90044-E_BIB61","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM196702162760703","article-title":"Aromatic amino acids and modification of Parkinsonism","volume":"276","author":"Cotzias","year":"1967","journal-title":"New Engl J Med"},{"key":"10.1016\/0006-3223(93)90044-E_BIB62","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of parkinsonism: chronic treatment with L-DOPA","volume":"280","author":"Cotzias","year":"1969","journal-title":"New Engl J Med"},{"key":"10.1016\/0006-3223(93)90044-E_BIB63","first-page":"1150","article-title":"More on amantadine in tardive dyskinesia","volume":"28","author":"Crane","year":"1971","journal-title":"New Engl J Med"},{"key":"10.1016\/0006-3223(93)90044-E_BIB64","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/archneur.1972.00490170058008","article-title":"PseudoParkinsonism and tardive dyskinesia","volume":"27","author":"Crane","year":"1972","journal-title":"Arch Neurol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB65","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1192\/bjp.122.4.395","article-title":"Persistent dyskinesia","volume":"122","author":"Crane","year":"1973","journal-title":"Br J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB66","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/archpsyc.1971.01750080083014","article-title":"Motor disorders induced by neuroleptics","volume":"24","author":"Crane","year":"1971","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB67","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00004714-198210000-00010","article-title":"Abnormal involuntary movements in schizophrenia: Are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors","volume":"2","author":"Crow","year":"1982","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB68","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJM198104303041807","article-title":"Depression dependent dyskinesia in two cases of manic depressive illness","volume":"304","author":"Culter","year":"1981","journal-title":"New Engl J Med"},{"key":"10.1016\/0006-3223(93)90044-E_BIB69","first-page":"129","article-title":"Neuroleptics; clinical use in psychiatry","volume":"Vol 10","author":"Davis","year":"1978"},{"key":"10.1016\/0006-3223(93)90044-E_BIB70","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1097\/00004714-198602001-00002","article-title":"The natural course of schizophrenia and effective maintenance drug treatment","volume":"6","author":"Davis","year":"1986","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB71","first-page":"125","article-title":"Tardive dyskinesia and depressive illness","volume":"2","author":"Davis","year":"1976","journal-title":"Psychopharmacol Commun"},{"key":"10.1016\/0006-3223(93)90044-E_BIB72","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/0024-3205(76)90095-3","article-title":"Choline in tardive dyskinesia and Huntington's disease","volume":"19","author":"Davis","year":"1976","journal-title":"Life Sci"},{"key":"10.1016\/0006-3223(93)90044-E_BIB73","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1056\/NEJM197110072851516","article-title":"Amantadine hydrochloride treatment of tardive dyskinesia","volume":"285","author":"Decker","year":"1971","journal-title":"New Engl J Med"},{"key":"10.1016\/0006-3223(93)90044-E_BIB74","first-page":"267","article-title":"Coexisting tardive dyskinesia and Parkinsonism: A case report","volume":"12","author":"De Fraites","year":"1977","journal-title":"Biol Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB75","series-title":"Neuropsychopharmacology","first-page":"608","article-title":"Persistent extrapyramidal side effects after long-term application of neuroleptics","author":"Degkwitz","year":"1967"},{"key":"10.1016\/0006-3223(93)90044-E_BIB76","first-page":"890","article-title":"Der zeitliche Zusammenhang zwischen dem Auftreten persistierenden extrapyramidaler Hyperkinesen und Psychorecidiven nach abrupte langfristiger Behandlung chronisch schizophrener Kranke","volume":"20","author":"Degkwitz","year":"1970","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/0006-3223(93)90044-E_BIB77","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0140-6736(92)90264-4","article-title":"Levodopa","volume":"339","author":"Deleu","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/0006-3223(93)90044-E_BIB78","series-title":"Alterations of Metabolites in the Nervous System","first-page":"363","article-title":"Anticonvulsants","author":"DeLorenzo","year":"1985"},{"key":"10.1016\/0006-3223(93)90044-E_BIB79","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/jnnp.46.7.666","article-title":"State-dependent tardive dyskinesia in manic depressive illness","volume":"46","author":"De Potter","year":"1983","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB80","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cne.902550208","article-title":"Synaptic organization of cholinergic neurons in the monkey striatum","volume":"255","author":"DiFiglia","year":"1987","journal-title":"J Comp Neurol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB81","first-page":"173","article-title":"Cholinergic hypothesis of depression: a reappraisal","volume":"9","author":"Disalver","year":"1989","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB82","first-page":"195","article-title":"Neuroleptic medication facilitates the natural occurrence of tardive dyskinesia. A critical review","volume":"88","author":"Driesens","year":"1988","journal-title":"Acta Psychiatr Belg"},{"key":"10.1016\/0006-3223(93)90044-E_BIB83","first-page":"369","article-title":"Cytometric study of the putamen in different types of Huntington's chorea","volume":"1","author":"Dom","year":"1973","journal-title":"Adv Neurol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB84","first-page":"854","article-title":"Oral dyskinesias: occurrence and treatment","volume":"31","author":"Dynes","year":"1970","journal-title":"Dis Nerv Syst"},{"key":"10.1016\/0006-3223(93)90044-E_BIB85","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0014-2999(77)90325-9","article-title":"Tolerance to haloperidol catalepsy","volume":"41","author":"Ezrin-Waters","year":"1977","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB86","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/mds.870070205","article-title":"Clozapine prevents recurrence of psychosis in Parkinson's disease","volume":"7","author":"Factor","year":"1992","journal-title":"Movement Disorders"},{"key":"10.1016\/0006-3223(93)90044-E_BIB87","first-page":"277","article-title":"Oral-facial-lingual dyskinesia due to anticholinergic medication","volume":"97","author":"Fahn","year":"1972","journal-title":"Trans Am Neurol Assoc"},{"key":"10.1016\/0006-3223(93)90044-E_BIB88","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0014-2999(88)90750-9","article-title":"Behavioural and biochemical effect of chronic treatment with D1 and\/or D2 dopamine agonists in MPTP monkeys","volume":"150","author":"Falardeau","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB89","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1176\/ajp.130.8.922","article-title":"Methylphenidate and tardive dyskinesia","volume":"130","author":"Fann","year":"1973","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB90","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00437417","article-title":"Cholinergic suppression of tardive dyskinesia","volume":"37","author":"Fann","year":"1974","journal-title":"Psychopharmacologia"},{"key":"10.1016\/0006-3223(93)90044-E_BIB91","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0165-1781(89)90212-6","article-title":"Neuroleptic non-response and affective symptoms: a 2-year prospective study of schizophrenic outpatients","volume":"28","author":"Faraone","year":"1989","journal-title":"Psychiatry Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB92","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1007\/BF00442555","article-title":"D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics","volume":"99","author":"Farde","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB93","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0447.1964.tb05731.x","article-title":"Neurological symptoms in pharmacotherapy of psychoses","volume":"40","author":"Faurbye","year":"1964","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/0006-3223(93)90044-E_BIB94","first-page":"391","article-title":"Dopaminergic psychoses in advanced Parkinson's disease","volume":"53","author":"Fischer","year":"1990","journal-title":"Adv Neurol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB95","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1016\/0006-2952(83)90397-0","article-title":"Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors but not with increase D-1 receptors","volume":"32","author":"Fleminger","year":"1983","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB96","first-page":"305","article-title":"High dose treatment of rats with perphenazine enanthate","volume":"50","author":"Fog","year":"1977","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB97","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1600-0404.1991.tb04918.x","article-title":"Psychotic complications of long-term levodopa reatment of Parkinson's disease","volume":"84","author":"Friedman","year":"1991","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/0006-3223(93)90044-E_BIB98","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.39.9.1219","article-title":"Clozapine in the treatment of psychosis in Parkinson's disease","volume":"39","author":"Friedman","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/0006-3223(93)90044-E_BIB99","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1055\/s-2007-1017019","article-title":"Predictors of neuroleptic treatment response in acute schizophrenia: results of a treatment study with perazine","volume":"21","author":"Gaebel","year":"1988","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB100","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0304-3940(87)90409-5","article-title":"Spontaneous synaptic potentials in dopamine denervated neostriatal neurones","volume":"81","author":"Galarraga","year":"1987","journal-title":"Neurosci Lett"},{"key":"10.1016\/0006-3223(93)90044-E_BIB101","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/archpsyc.1977.01770200085010","article-title":"Catatonic reactions to high-potency neuroleptic drugs","volume":"34","author":"Gelenberg","year":"1977","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB102","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF00421217","article-title":"Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia","volume":"34","author":"Gerlach","year":"1974","journal-title":"Psychopharmacologia"},{"key":"10.1016\/0006-3223(93)90044-E_BIB103","series-title":"Clinical Pharmacology in Psychiatry","first-page":"236","article-title":"Effect of selective D1 and D2 dopamine receptor antagonists and agonists in cebus monkeys: implications for acute and tardive dyskinesias. A preliminary report","author":"Gerlach","year":"1987"},{"key":"10.1016\/0006-3223(93)90044-E_BIB104","first-page":"363","article-title":"\u00c9tude pilot des effets d'un antiparkinsonian anticholinergique au cours detats depressifs","volume":"1","author":"Gisselman","year":"1975","journal-title":"Encephale"},{"key":"10.1016\/0006-3223(93)90044-E_BIB105","first-page":"53","article-title":"Persistence of fluphenazine in plasma after decanoate withdrawal","volume":"8","author":"Gitkin","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB106","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/archpsyc.1984.01790170097011","article-title":"Tardive dyskinesia: a discontinuation study","volume":"41","author":"Glazer","year":"1984","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB107","first-page":"587","article-title":"Tardive dyskinesia: neuropsychological, computerized tomographic, and psychiatric symptom findings","volume":"30","author":"Gold","year":"1991","journal-title":"Br J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB108","first-page":"409","article-title":"Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-DOPA in 1-methyl-4-phenyl,1,2,3,6-tetrahydropyridine treated monkeys","volume":"259","author":"Gomez-Mancilla","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/0006-3223(93)90044-E_BIB109","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/mds.870020106","article-title":"Antiparkinsonian activity of a single oral dose of PHNO","volume":"2","author":"Grandas","year":"1987","journal-title":"Movement Disorders"},{"key":"10.1016\/0006-3223(93)90044-E_BIB110","series-title":"Paper presented at ACNP Annual Meeting","article-title":"The rate of neuroleptic dose reduction affects relapse rate in remitted schizophrenic patients","author":"Green","year":"1989"},{"key":"10.1016\/0006-3223(93)90044-E_BIB111","first-page":"195","article-title":"Zur Neuropathologie der persistierenden choreiform Hyperkinesien unter neuroleptische Langzeittherapie","volume":"2","author":"Gross","year":"1970","journal-title":"Psyhofarmakologija (Zagreb)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB112","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/ajp.141.1.20","article-title":"Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents","volume":"141","author":"Gualtieri","year":"1984","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB113","first-page":"139","article-title":"Risk factors for drug-induced Parkinsonism in tardive dyskinesia patients","volume":"49","author":"Hansen","year":"1988","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB114","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1176\/ajp.144.6.727","article-title":"The Vermont Longitudinal Study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM III criteria for schizophrenia","volume":"144","author":"Harding","year":"1987","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF00499253","article-title":"Modulation by endogenous dopamine of the release of acetylcholine in caudate nucleus of the rabbit","volume":"315","author":"Herrting","year":"1980","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0920-9964(91)90048-V","article-title":"Computed tomographic evaluation of patients with tardive dyskinesia","volume":"5","author":"Hoffman","year":"1991","journal-title":"Schizophr Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB117","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/archpsyc.1973.01750310038007","article-title":"Drug and sociotherapy in the aftercare of schizophrenic patients","volume":"28","author":"Hogarty","year":"1973","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB118","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archpsyc.1974.01760170005001","article-title":"Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two year relapse rates","volume":"31","author":"Hogarty","year":"1974","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB119","first-page":"1466","article-title":"Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients","volume":"39","author":"Hollister","year":"1982","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB120","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jnnp.53.3.224","article-title":"Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia","volume":"53","author":"Horstink","year":"1990","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB121","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00004850-198701000-00006","article-title":"Treatment-resistant schizophrenia: controlled study of moderate- and high-dose thiothixene","volume":"2","author":"Huang","year":"1987","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB122","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1001\/archpsyc.1987.01800130111024","article-title":"Prolonged pharmacologic activity of neuroleptic drugs","volume":"44","author":"Hubbard","year":"1987","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB123","first-page":"258","article-title":"Neuroleptic-induced supersensitivity psychosis: retrospective study of schizophrenic inpatients","volume":"49","author":"Hunt","year":"1988","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB124","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0022-510X(68)90148-2","article-title":"Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication","volume":"7","author":"Hunter","year":"1968","journal-title":"J Neurol Sci"},{"key":"10.1016\/0006-3223(93)90044-E_BIB125","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1600-0447.1990.tb03069.x","article-title":"A statistical trial of subclassification for tardive dyskinesia","volume":"82","author":"Inada","year":"1990","journal-title":"Acta Psychiat Scand"},{"key":"10.1016\/0006-3223(93)90044-E_BIB126","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0006-8993(89)91686-7","article-title":"Spine density on neostriatal neurons changes with 6-hydroxydopamine lesions and with age","volume":"503","author":"Ingham","year":"1989","journal-title":"Brain Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB127","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/070674378803300701","article-title":"Carbamazepine in psychiatry: a review","volume":"33","author":"Israel","year":"1988","journal-title":"Can J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB128","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0010-440X(66)80028-7","article-title":"Therapeutic studies in \u201ctherapy resistant\u201d schizophrenic patients","volume":"7","author":"Itil","year":"1966","journal-title":"Compr Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB129","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1176\/ajp.131.8.910","article-title":"Tardive and withdrawal dyskinesia associated with haloperidol","volume":"131","author":"Jacobsen","year":"1974","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB130","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1056\/NEJM197204062861424","article-title":"Effects of amantadine on tardive dyskinesia and pseudoParkinsonian","volume":"286","author":"Janowsky","year":"1972","journal-title":"New Engl J Med"},{"key":"10.1016\/0006-3223(93)90044-E_BIB131","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(72)93021-8","article-title":"A cholinergic-adrenergic hypothesis of mania and depression","volume":"ii","author":"Janowsky","year":"1972","journal-title":"Lancet"},{"key":"10.1016\/0006-3223(93)90044-E_BIB132","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1176\/ajp.130.12.1370","article-title":"Antagonistic effects of physostigmine and methylphenidate in man","volume":"130","author":"Janowsky","year":"1973","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB133","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00006842-197405000-00008","article-title":"Acetylcholine and depression","volume":"36","author":"Janowsky","year":"1974","journal-title":"Psychosom Med"},{"key":"10.1016\/0006-3223(93)90044-E_BIB134","first-page":"331","article-title":"Tardive dyskinesia with schizophrenic relapse","volume":"33","author":"Jawed","year":"1989","journal-title":"J Ment Defic Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB135","series-title":"Neurotoxicology","first-page":"25","article-title":"Neuropathologic findings after neuroleptic long term treatment","author":"Jellinger","year":"1977"},{"key":"10.1016\/0006-3223(93)90044-E_BIB136","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1176\/ajp.138.3.297","article-title":"Changing epidemiology of tardive dyskinesia. An overview","volume":"138","author":"Jeste","year":"1981","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB137","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/archpsyc.1982.04290070037008","article-title":"Therapeutic strategies against tardive dyskinesia","volume":"39","author":"Jeste","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB138","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/BF02801966","article-title":"Neuropathological changes following 4, 8 and 12 months of treatment with fluphenazine in rats","volume":"106","author":"Jeste","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB139","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(78)90193-9","article-title":"Mechanism of the antipsychotic effect in the treatment of acute schizophrenia","volume":"i","author":"Johnstone","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/0006-3223(93)90044-E_BIB140","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1017\/S0033291700047942","article-title":"Adverse effects of anticholinergic medications on positive schizophrenic symptoms","volume":"13","author":"Johnstone","year":"1983","journal-title":"Psychol Med"},{"key":"10.1016\/0006-3223(93)90044-E_BIB141","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/070674378903400312","article-title":"Rebound psychosis following the discontinuation of high-potency neuroleptic","volume":"34","author":"Kahne","year":"1989","journal-title":"Can J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB142","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archpsyc.1982.04290040069010","article-title":"Tardive dyskinesia: prevalence and risk factors 1959\u20131979","volume":"36","author":"Kane","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB143","series-title":"Dyskinesia\u2014research and treatment (Psychopharmacology Supplementum 2)","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/978-3-642-70140-5_9","article-title":"Tardive dyskinesia: prevalence, incidence and risk factors","author":"Kane","year":"1985"},{"key":"10.1016\/0006-3223(93)90044-E_BIB144","first-page":"254","article-title":"Integrating incidence and prevalence of tardive dyskinesia","volume":"22","author":"Kane","year":"1986","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/0006-3223(93)90044-E_BIB145","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB146","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/BF00442561","article-title":"Clozapine for the treatment-resistant schizophrenic: results of a US multicenter trial","volume":"99","author":"Kane","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB147","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF01250702","article-title":"Positron emission tomography with [18F]-methylspiperone demonstrates D2 dopamine receptor binding differences with haloperidol and clozapine","volume":"86","author":"Karbe","year":"1991","journal-title":"J Neural Transm"},{"key":"10.1016\/0006-3223(93)90044-E_BIB148","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/0010-440X(85)90096-3","article-title":"Tardive dyskinesia and psychopathology in chronic schizophrenia: a cross-sectional study","volume":"26","author":"Karson","year":"1985","journal-title":"Compr Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB149","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1176\/ajp.130.4.479","article-title":"Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine","volume":"130","author":"Kazamatsuri","year":"1973","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB150","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/jnnp.52.1.72","article-title":"Asymptometry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations","volume":"52","author":"Kempster","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB151","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/jnnp.52.6.718","article-title":"Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease","volume":"52","author":"Kempster","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB152","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00005053-199204000-00009","article-title":"The concept of supersensitivity psychosis","volume":"180","author":"Kirkpatrick","year":"1992","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/0006-3223(93)90044-E_BIB153","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1176\/ajp.130.1.82","article-title":"The pharmacology of tardive dyskinesia","volume":"130","author":"Klawans","year":"1973","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB154","series-title":"Parkinson's disease and movement disorders","first-page":"315","article-title":"The pathophysiology of drug-induced movement disorders","author":"Klawans","year":"1988"},{"key":"10.1016\/0006-3223(93)90044-E_BIB155","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/jnnp.37.8.941","article-title":"Effect of cholinergic and anticholinergic agents on tardive dyskinesia","volume":"37","author":"Klawans","year":"1974","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB156","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ana.410020207","article-title":"Levodopa-induced dopamine receptor hypersensitivity","volume":"2","author":"Klawans","year":"1977","journal-title":"Ann Neurol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB157","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1176\/ajp.137.8.900","article-title":"Tardive dyskinesia: a review and update","volume":"137","author":"Klawans","year":"1980","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01250639","article-title":"3H-Spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movement and positive symptoms","volume":"75","author":"Kornhuber","year":"1989","journal-title":"J Neural Transm"},{"key":"10.1016\/0006-3223(93)90044-E_BIB159","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0006-8993(87)90226-5","article-title":"Neostriatal cholinergic neurons receive direct synaptic inputs from dopaminergic axons","volume":"415","author":"Kubota","year":"1987","journal-title":"Brain Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB160","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00005053-198004000-00004","article-title":"Tardive dyskinesia and hospital discharge","volume":"168","author":"Kucharski","year":"1980","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/0006-3223(93)90044-E_BIB161","first-page":"178","article-title":"Ein eigentumliches Syndrom im oralen Bereich bei Megephenapplication","volume":"27","author":"Kulenkampff","year":"1956","journal-title":"Nervenarzt"},{"key":"10.1016\/0006-3223(93)90044-E_BIB162","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00508472","article-title":"Specific effect of haloperidol on dopamine turnover in the frontal cortex","volume":"296","author":"Laduron","year":"1977","journal-title":"Naunyn Schmiedelbergs Arch Pharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB163","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/BF00441944","article-title":"Differential tolerance to cateloptogenic effects of SCH 23390 and haloperidol after repeated administration","volume":"98","author":"Lappalainen","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB164","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/jnnp.44.11.1020","article-title":"Sustained bromocriptive therapy in previously untreated patients with Parkinson's disease","volume":"44","author":"Lees","year":"1981","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB165","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/0306-4522(83)90102-1","article-title":"The striatal cholinergic interneuron: synaptic target of dopaminergic terminals?","volume":"4","author":"Lehmann","year":"1983","journal-title":"Neuroscience"},{"key":"10.1016\/0006-3223(93)90044-E_BIB166","first-page":"471","article-title":"Therapeutic effects of clozapine. A 4-year follow-up of a controlled clinical trial","volume":"59","author":"Leon","year":"1979","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/0006-3223(93)90044-E_BIB167","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.29.9_Part_1.1253","article-title":"Analysis of the clinical problems in Parkinsonism and the complications of long-term levodopa therapy","volume":"29","author":"Lesser","year":"1979","journal-title":"Neurology"},{"issue":"suppl 1","key":"10.1016\/0006-3223(93)90044-E_BIB168","first-page":"258","article-title":"Selective D-1 agonist (SKF 38393) in Parkinsonism","volume":"38","author":"LeWitt","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/0006-3223(93)90044-E_BIB169","first-page":"140","article-title":"Clozapine: clinical evidence of novel effects","volume":"9","author":"Lieberman","year":"1986","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB170","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/BF00442560","article-title":"Clozapine pharmacology and tardive dyskinesia","volume":"99","author":"Lieberman","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB171","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1600-0404.1978.tb02871.x","article-title":"Deanol and physostigmine in the treatment of I-DOPA induced dyskinesias","volume":"58","author":"Lindeboom","year":"1978","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/0006-3223(93)90044-E_BIB172","first-page":"117","article-title":"Radioreceptor assay of neuroleptics in refractory chronic schizophrenia patients","volume":"45","author":"Lindenmayer","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB173","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1471-4159.1975.tb04409.x","article-title":"Distribution of choline acetyltransferase and glutamate decarboxylase within the substantia nigra and in other brain regions from control and Parkinsonian patients","volume":"25","author":"Lloyd","year":"1975","journal-title":"J Neurochem"},{"key":"10.1016\/0006-3223(93)90044-E_BIB174","first-page":"97","article-title":"Neurological aspects of tardive dyskinesia","author":"Lohr","year":"1986"},{"key":"10.1016\/0006-3223(93)90044-E_BIB175","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-2999(88)90611-5","article-title":"Behavioural effects of dopamine D-1 and D-2 receptor agonists in monkeys previously treated with haloperidol","volume":"153","author":"Lublin","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB176","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00004714-198902000-00008","article-title":"Stable remission of tardive dyskinesia by L-DOPA","volume":"9","author":"Ludatscher","year":"1989","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB177","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0166-2236(87)90025-7","article-title":"Glutamate dysfunction in Alzheimer's disease: an hypothesis","volume":"10","author":"Maragos","year":"1987","journal-title":"Trends Neurosci"},{"key":"10.1016\/0006-3223(93)90044-E_BIB178","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cpt1971122part2340","article-title":"The choreoathetoid movement disorder induced by levodopa","volume":"12","author":"Markham","year":"1971","journal-title":"Clin Pharmac Ther"},{"key":"10.1016\/0006-3223(93)90044-E_BIB179","first-page":"153","article-title":"Dopamine sensitive adenylate cyclase and dopamine\/neuroleptic receptor binding: effect of neuroleptic drugs","volume":"24","author":"Marshall","year":"1980","journal-title":"Adv Biochem Psychopharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-2999(83)90604-0","article-title":"Differential effects of acute and chronic administration of haloperidol on homovanillic acid levels in discrete areas of rat brain","volume":"89","author":"Matsumoto","year":"1983","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB181","series-title":"Treatment resistance in schizophrenia. An approach for research and clinical routine together with a reconnaissance paper","first-page":"22","article-title":"Systematic approach to treatment resistance in schizophrenic disorders","author":"May","year":"1988"},{"key":"10.1016\/0006-3223(93)90044-E_BIB182","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1192\/bjp.131.3.310","article-title":"High-dosage haloperidol in chronic schizophrenia","volume":"131","author":"McCreadie","year":"1977","journal-title":"Br J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB183","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/archneur.1971.00490030091011","article-title":"Cholinergic enzyme systems in Parkinson's disease","volume":"25","author":"McGeer","year":"1971","journal-title":"Arch Neurol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB184","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0014-2999(85)90732-0","article-title":"Chronic neuroleptic treatment increased D-2 but not D-1 receptors in rat striatum","volume":"113","author":"McKenzie","year":"1985","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB185","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0006-8993(88)90124-2","article-title":"Atrophy of medium spiny I striatal dendrities in advanced Parkinson's disease","volume":"455","author":"McNeill","year":"1988","journal-title":"Brain Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB186","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM197001012820102","article-title":"Modification of chronic manganese poisoning. Treatment with L-DOPA or 5-OH-tryptophan","volume":"282","author":"Mena","year":"1970","journal-title":"New Engl J Med"},{"key":"10.1016\/0006-3223(93)90044-E_BIB187","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1056\/NEJM197202032860522","article-title":"Amantadine in tardive dyskinesia (cont.)","volume":"286","author":"Merren","year":"1972","journal-title":"New Engl J Med"},{"key":"10.1016\/0006-3223(93)90044-E_BIB188","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0306-4522(84)90163-5","article-title":"Atlas of cholinergic neurons in the forebrain and upper brainstem of the macaque based on monclonal choline acetyltransferase histochemistry","volume":"12","author":"Mesulam","year":"1984","journal-title":"Neuroscience"},{"key":"10.1016\/0006-3223(93)90044-E_BIB189","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1017\/S0033291700019759","article-title":"Major psychosis and dopamine: controversial features and some suggestions","volume":"14","author":"Miller","year":"1984","journal-title":"Psychol Med"},{"key":"10.1016\/0006-3223(93)90044-E_BIB190","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF00176470","article-title":"The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness","volume":"92","author":"Miller","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB191","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0301-0082(89)90034-8","article-title":"Schizophrenia as a progressive disorder: relations to EEG, CT, neuropathological and other evidence","volume":"33","author":"Miller","year":"1989","journal-title":"Prog Neurobiol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB192","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0301-0082(90)90005-2","article-title":"Dopamine D-1 and D-2 receptors in relation to reward and performance: a case for the D-1 receptor as a primary site of therapeutic action of neuroleptic drugs","volume":"34","author":"Miller","year":"1990","journal-title":"Prog Neurobiol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB193","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0925-4927(91)90007-D","article-title":"MRI abnormalities in tardive dyskinesia","volume":"40","author":"Mion","year":"1991","journal-title":"Psychiatry Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB194","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/BF02439593","article-title":"Neuroleptic-induced oral dyskinesias: effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and cholineacetyltransferase activities","volume":"93","author":"Mithani","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB195","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF00347089","article-title":"Uber die depressogene Wirkung von Physostigmin","volume":"218","author":"Modestin","year":"1973","journal-title":"Arch Psychiatr Nerv-Krankh"},{"key":"10.1016\/0006-3223(93)90044-E_BIB196","first-page":"197","article-title":"Levodopa-induced dyskinesia in the normal monkey","volume":"39","author":"Mones","year":"1972","journal-title":"J Mt Sinai Hosp"},{"key":"10.1016\/0006-3223(93)90044-E_BIB197","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jnnp.34.6.668","article-title":"Analysis of L-DOPA induced dyskinesias in 51 patients with Parkinsonism","volume":"34","author":"Mones","year":"1971","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB198","first-page":"234","article-title":"The modification of L-DOPA-induced dyskinesias in the monkey by unilateral nigral lesions","volume":"98","author":"Mones","year":"1973","journal-title":"Trans Am Neurol Assoc"},{"key":"10.1016\/0006-3223(93)90044-E_BIB199","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1192\/bjp.157.1.41","article-title":"The positive:negative dichotomy in schizophrenia","volume":"157","author":"Mortimer","year":"1990","journal-title":"Br J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB200","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ana.410240304","article-title":"Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms","volume":"24","author":"Mouradian","year":"1988","journal-title":"Ann Neurol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB201","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ana.410250521","article-title":"Pathogenesis of dyskinesias in Parkinson's disease","volume":"25","author":"Mouradian","year":"1989","journal-title":"Ann Neurol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB202","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archpsyc.1982.04290040064009","article-title":"Tardive dyskinesia in psychiatric outpatients. A study of prevalence and association with demography, clinical and drug history variables","volume":"39","author":"Mukherjee","year":"1982","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/0006-3223(93)90044-E_BIB203","first-page":"22","article-title":"Carbamazepine in nonresponsive psychosis","volume":"49","author":"Neppe","year":"1988","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB204","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00428036","article-title":"Evidence for cell loss in corpus striatum after long term treatment with a neuroleptic drug (flupenthixol) in rats","volume":"59","author":"Nielsen","year":"1978","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB205","first-page":"261","article-title":"Phenothiazine treatment in acute schizophrenia","volume":"10","year":"1964","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB206","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0006-8993(86)91481-2","article-title":"Long term effects of dopamine depleting brain lesions on spontaneous activity of type II striatal neurons: relation to behavioural recovery","volume":"398","author":"Nisenbaum","year":"1986","journal-title":"Brain Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB207","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1523\/JNEUROSCI.08-11-04138.1988","article-title":"Evidence for two functionally distinct subpopulations of neurons within the rat striatum","volume":"8","author":"Nisenbaum","year":"1988","journal-title":"J Neurosci"},{"key":"10.1016\/0006-3223(93)90044-E_BIB208","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0006-8993(88)90872-4","article-title":"Spontaneous activity of type II, but not type I striatal neurons is correlated with recovery of behavioural function after dopamine depleting brain lesions","volume":"473","author":"Nisenbaum","year":"1988","journal-title":"Brain Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB209","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0304-3940(85)90037-0","article-title":"The dopamine D2 agonist LY 141865 but not the D1 agonist SKF 38393 reverses Parkinsonism induced by 1-methyl-4-phenyl,1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset","volume":"57","author":"Nomoto","year":"1985","journal-title":"Neurosci Lett"},{"key":"10.1016\/0006-3223(93)90044-E_BIB210","first-page":"223","article-title":"Topographic distribution of choline acetyltransferase activity and muscarinic and nicotinic receptors in Parkinson brains","volume":"3","author":"Nordberg","year":"1985","journal-title":"Neurochem Pathol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB211","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/271557a0","article-title":"Glutamate neurotoxicity and Huntington's chorea","volume":"271","author":"Olney","year":"1978","journal-title":"Nature"},{"key":"10.1016\/0006-3223(93)90044-E_BIB212","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0022-3956(79)90024-4","article-title":"Effects of lithium on the physostigmine-induced behavioural syndrome and plasma cyclic GMP","volume":"14","author":"Oppenheim","year":"1979","journal-title":"J Psychiatry Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB213","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0006-8993(86)90895-4","article-title":"Dopamine depletion increases spontaneous activity in striatal neurones","volume":"376","author":"Orr","year":"1986","journal-title":"Brain Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB214","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0006-3223(86)90007-7","article-title":"Selective breeding for increased cholinergic function: development of a new animal model of depression","volume":"21","author":"Overstreet","year":"1986","journal-title":"Biol Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB215","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-8993(84)91044-8","article-title":"Selective breeding for differences in cholinergic function. Pre- and post-synaptic mechanisms involved in sensitivity to the anticholinesterase, DFP","volume":"294","author":"Overstreet","year":"1984","journal-title":"Brain Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB216","first-page":"253","article-title":"Response to clozapine in chronic psychotic patients","volume":"25","author":"Owen","year":"1989","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/0006-3223(93)90044-E_BIB217","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00004714-198812000-00023","article-title":"Persistence of neuroleptic drugs in plasma and body tissues","volume":"8","author":"Pajari","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB218","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF00429280","article-title":"The long-term effect of perphenazine enanthate on the rat brain. Some metabolic and anatomical observations","volume":"29","author":"Pakkenberg","year":"1973","journal-title":"Psychopharmacologia"},{"key":"10.1016\/0006-3223(93)90044-E_BIB219","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00421366","article-title":"Short-term effect of perphenazine enanthate on the rat brain","volume":"40","author":"Pakkenberg","year":"1974","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB220","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1176\/ajp.144.8.1084","article-title":"Absence of acquired tolerance to neuroleptics in schizophrenic patients","volume":"144","author":"Palmstierna","year":"1987","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB221","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0014-2999(90)94059-7","article-title":"The effects of dopamine D-1 and D-2 agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment","volume":"186","author":"Peacock","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB222","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0091-3057(88)90304-8","article-title":"Enhanced benzodiazepine responsiveness in rats with increased cholinergic function","volume":"31","author":"Pepe","year":"1988","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/0006-3223(93)90044-E_BIB223","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1600-0447.1985.tb02636.x","article-title":"Change in mental condition, hyperkinesias and biochemical parameters after withdrawal of chronic neuroleptic treatment","volume":"72","author":"Perenyi","year":"1985","journal-title":"Acta Psychiat Scand"},{"key":"10.1016\/0006-3223(93)90044-E_BIB224","first-page":"231","article-title":"Clozapine and norclozapine concentrations and clinical response of treatment refractory schizophrenic patients","volume":"148","author":"Perry","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB225","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1749-6632.1957.tb40764.x","article-title":"The inhibition of conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain","volume":"66","author":"Pfeiffer","year":"1957","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/0006-3223(93)90044-E_BIB226","first-page":"35","article-title":"Time course of clinical effects of carbamazepine: implications for mechanisms of action","volume":"49","author":"Post","year":"1988","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB227","first-page":"403","article-title":"Progressive effects of cocaine in behaviour and central amine metabolism in Rhesus monkeys: relationship to kindling and psychosis","volume":"11","author":"Post","year":"1976","journal-title":"Biol Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB228","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1176\/ajp.134.1.84","article-title":"Tardive dyskinesia: are the first signs reversible?","volume":"134","author":"Quitkin","year":"1977","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB229","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/0024-3205(85)90081-5","article-title":"Quantification of dopaminergic supersensitivity using apomorphine induced behaviour in the mouse","volume":"37","author":"Randall","year":"1985","journal-title":"Life Sci"},{"key":"10.1016\/0006-3223(93)90044-E_BIB230","first-page":"695","article-title":"Aging and the regulation of striatal dopaminergic mechanisms in mice","volume":"219","author":"Randall","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/0006-3223(93)90044-E_BIB231","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/jnnp.42.2.143","article-title":"Long-term treatment of Parkinson's disease with bromocriptine","volume":"42","author":"Rascol","year":"1979","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB232","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0024-3205(77)90514-8","article-title":"Neurotransmitter receptor alterations in Parkinson's disease","volume":"21","author":"Reisine","year":"1977","journal-title":"Life Sci"},{"key":"10.1016\/0006-3223(93)90044-E_BIB233","first-page":"112","article-title":"Parenteral haloperidol for rapid control of severe disruptive symptoms of acute schizophrenia","volume":"35","author":"Reschke","year":"1974","journal-title":"Dis Nerv Syst"},{"key":"10.1016\/0006-3223(93)90044-E_BIB234","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF01245368","article-title":"Dopamine receptor abnormalities in the striatum and pallidum in tardive dyskinesia: a postmortem study","volume":"87","author":"Reynolds","year":"1992","journal-title":"J Neural Transm"},{"key":"10.1016\/0006-3223(93)90044-E_BIB235","first-page":"130","article-title":"Tardive dyskinesia and depressive symptoms in schizophrenics","volume":"21","author":"Richardson","year":"1985","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/0006-3223(93)90044-E_BIB236","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/archpsyc.1975.01760230138011","article-title":"Akinesia: a poorly recognized drug-induced extrapyramidal behavioural disorder","volume":"32","author":"Rifkin","year":"1975","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB237","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0006-8993(91)90554-9","article-title":"A post-mortem study on striatal dopamine receptors in Parkinson's disease","volume":"556","author":"Rinne","year":"1991","journal-title":"Brain Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB238","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1600-0404.1983.tb01513.x","article-title":"Problems associated with long-term levodopa treatment of Parkinson's disease","volume":"95","author":"Rinne","year":"1983","journal-title":"Acta Neurol Scand (Suppl)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB239","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1600-0404.1973.tb01293.x","article-title":"Brain acetylcholinesterase in Parkinson's disease","volume":"49","author":"Rinne","year":"1973","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/0006-3223(93)90044-E_BIB240","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0165-1781(81)90012-3","article-title":"Physostigmine induction of depressive symptomatology in normal human subjects","volume":"4","author":"Risch","year":"1981","journal-title":"Psychiatry Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB241","first-page":"361","article-title":"Movement disorders in patients with coexistent neuroleptic-induced tremor and tardive dyskinesia: EMG and pharmacological study","volume":"45","author":"Rondot","year":"1986","journal-title":"Adv Neurol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB242","first-page":"423","article-title":"Tardive dyskinesia: relationship with a primary affective disorder","volume":"38","author":"Rosenbaum","year":"1977","journal-title":"Dis Nerv Syst"},{"key":"10.1016\/0006-3223(93)90044-E_BIB243","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0006-8993(82)90615-1","article-title":"Muscarinic binding and cholineacetyltransferase activity in Parkinsonian subjects with reference to dementia","volume":"232","author":"Ruberg","year":"1982","journal-title":"Brain Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB244","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/BF00427817","article-title":"Cholinergic manipulation of perioral behaviour induced by chronic neuroleptic administration to rats","volume":"79","author":"Rupniak","year":"1983","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB245","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00002826-198606000-00006","article-title":"Differential alterations in striatal acetylcholine function in rats during 12 months continuous administration of haloperidol, sulpiride or clozapine","volume":"9","author":"Rupniak","year":"1986","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB246","first-page":"387","article-title":"Depression as a risk factor in tardive dyskinesia","volume":"17","author":"Rush","year":"1982","journal-title":"Biol Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB247","first-page":"347","article-title":"The central effects of scopolamine in man","volume":"3","author":"Safer","year":"1971","journal-title":"Biol Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB248","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00421063","article-title":"Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine","volume":"41","author":"Sayers","year":"1975","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB249","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0014-2999(77)90230-8","article-title":"Differential regional development of the tolerance to increase in dopamine turnover upon repeated neuroleptic administration","volume":"46","author":"Scatton","year":"1977","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB250","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1016\/0024-3205(82)90679-8","article-title":"Further evidence for the involvement of D2 but not D1 dopamine receptors in dopaminergic control of striatal cholinergic transmission","volume":"31","author":"Scatton","year":"1982","journal-title":"Life Sci"},{"key":"10.1016\/0006-3223(93)90044-E_BIB251","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1126\/science.2508225","article-title":"Protection of dentate hilar cells from prolonged stimulation by intracellular calcium chelation","volume":"246","author":"Scharfman","year":"1989","journal-title":"Science"},{"key":"10.1016\/0006-3223(93)90044-E_BIB252","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0091-3057(89)90372-9","article-title":"Levodopa-induced dyskinesias in Parkinsonian monkeys: relationship to extent of nigrostriatal damage","volume":"34","author":"Schneider","year":"1989","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/0006-3223(93)90044-E_BIB253","first-page":"35","article-title":"Ein Eigentumliches Syndrom im oralen Bereich bei Megaphen Application","volume":"28","author":"Schonecker","year":"1957","journal-title":"Nervenarzt"},{"key":"10.1016\/0006-3223(93)90044-E_BIB254","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/BF02244615","article-title":"Intermittent and continuous haloperidol regimes produce different types of oral dyskinesia in rats","volume":"100","author":"See","year":"1990","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB255","first-page":"751","article-title":"Quatre cas de dyskinesie facio-bucco-linguo-masticatrice a evolution prolongee secondaire a un traitement par les neuroleptiques","volume":"100","author":"Sigwald","year":"1959","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB256","first-page":"258","article-title":"Therapeutic reversal with benztropine in schizophrenics","volume":"169","author":"Singh","year":"1973","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/0006-3223(93)90044-E_BIB257","first-page":"263","article-title":"Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity and treatment-resistant psychosis","volume":"43","author":"Small","year":"1987","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB258","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/archpsyc.1980.01780250054006","article-title":"Change in prevalence, severity and recovery in tardive dyskinesia with age","volume":"37","author":"Smith","year":"1980","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB259","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00004714-198712000-00023","article-title":"Persistence of plasma neuroleptic levels after drug discontinuation","volume":"7","author":"Sramek","year":"1987","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB260","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/106002809002400101","article-title":"Patterns of neuroleptic usage in continuously hospitalized chronic schizophrenic patients: evidence for development of drug tolerance","volume":"24","author":"Sramek","year":"1990","journal-title":"DICP (Ann Pharmacother)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB261","first-page":"427","article-title":"Neuroleptic-induced reinnervation sprouting in the central nervous system (a model for the development of tardive dyskinesia and supersensitivity psychosis)","volume":"41","author":"Staton","year":"1980","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB262","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1600-0447.1990.tb05477.x","article-title":"Neuroleptic-induced supersensitivity psychosis in patients with bipolar affective disorder","volume":"81","author":"Steiner","year":"1990","journal-title":"Acta Psychiat Scand"},{"key":"10.1016\/0006-3223(93)90044-E_BIB263","first-page":"525","article-title":"Long-term effects of bromocriptine given to de novo patients with idiopathic Parkinson's disease","volume":"45","author":"Stern","year":"1986","journal-title":"Adv Neurol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB264","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/BF00451690","article-title":"Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective D1 and D2 receptor antagonists","volume":"98","author":"Stoessel","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB265","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0014-2999(82)90204-7","article-title":"Stimulation of D-2 dopamine receptors in rat neostriatum inhibits release of acetyl choline and dopamine but does not affect the release of gamma-aminobutyric acid, glutamate or serotonin","volume":"84","author":"Stoff","year":"1982","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB266","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/0006-8993(87)90864-X","article-title":"Stimulation of D-2 receptors in rat nucleus accumbens slices inhibits dopamine and actylcholine release, but not cyclic AMP formation","volume":"423","author":"Stoff","year":"1987","journal-title":"Brain Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB267","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1192\/bjp.143.6.597","article-title":"Cognitive dysfunction and tardive dyskinesia","volume":"143","author":"Struve","year":"1983","journal-title":"Br J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB268","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0278-5846(90)90031-B","article-title":"Antiepileptic drugs in the treatment of neuroleptic-induced supersensitivity psychosis","volume":"14","author":"Sultan","year":"1990","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB269","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0165-1781(88)90087-X","article-title":"CT abnormalities in tardive dyskinesia","volume":"26","author":"Swayze","year":"1988","journal-title":"Psychiatry Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB270","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0006-8993(90)90744-V","article-title":"Atrophy of the ipsilateral substantia nigra following middle cerebral artery occlusion in the rat","volume":"510","author":"Tamura","year":"1990","journal-title":"Brain Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB271","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/0028-3908(74)90084-7","article-title":"Behavioural supersensitivity to apomorphine following treatment with drugs which interfere with synaptic function of catecholamines","volume":"13","author":"Tarsy","year":"1974","journal-title":"Neuropharmacology"},{"key":"10.1016\/0006-3223(93)90044-E_BIB272","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1212\/WNL.24.1.28","article-title":"Physostigmine in choreiform movement disorders","volume":"24","author":"Tarsy","year":"1974","journal-title":"Neurology"},{"key":"10.1016\/0006-3223(93)90044-E_BIB273","first-page":"29","article-title":"The tardive dyskinesia syndrome","volume":"Vol. 1","author":"Tarsy","year":"1976"},{"key":"10.1016\/0006-3223(93)90044-E_BIB274","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0014-2999(91)90508-N","article-title":"Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced Parkinsonism in monkeys","volume":"199","author":"Taylor","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/0006-3223(93)90044-E_BIB275","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/00005053-197909000-00008","article-title":"And if that doesn't work, what next\u2026? A study of treatment failures in schizophrenia","volume":"167","author":"Tuma","year":"1979","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/0006-3223(93)90044-E_BIB276","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1176\/ajp.137.2.187","article-title":"Clinical state and neuroleptic serum levels measured by radioreceptor assay in schizophrenia","volume":"137","author":"Tune","year":"1980","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB277","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005053-198101000-00009","article-title":"Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenic patients","volume":"169","author":"Tune","year":"1981","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/0006-3223(93)90044-E_BIB278","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/BF00441188","article-title":"Reversible and irreversible dyskinesia after treatment with perphenzine, chlorpromazine, reserpine and electroconvulsive therapy","volume":"1","author":"Uhrbrand","year":"1969","journal-title":"Psychopharmacologia"},{"key":"10.1016\/0006-3223(93)90044-E_BIB279","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1055\/s-0028-1094618","article-title":"Reversal of neuroleptic-induced stupor by procyclidin. Two case reports and their theoretical implications","volume":"12","author":"Ungvari","year":"1979","journal-title":"Pharmakopsychiat"},{"key":"10.1016\/0006-3223(93)90044-E_BIB280","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/syn.890070402","article-title":"Morphometric study of synaptic patterns in the rat caudate nucleus and hippocampus under haloperidol treatment","volume":"7","author":"Uranova","year":"1991","journal-title":"Synapse"},{"key":"10.1016\/0006-3223(93)90044-E_BIB281","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM197103252841216","article-title":"Amantadine for dyskinesia tardis","volume":"284","author":"Vales","year":"1971","journal-title":"New Engl J Med"},{"key":"10.1016\/0006-3223(93)90044-E_BIB282","first-page":"375","article-title":"Mesoridazine and thioridazine: clinical effects and blood levels in refractory patients","volume":"47","author":"Vital-Herne","year":"1986","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB283","first-page":"88","article-title":"Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment","volume":"193","author":"Von Voigtlander","year":"1975","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/0006-3223(93)90044-E_BIB284","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1126\/science.6132447","article-title":"Spontaneous oro-facial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment","volume":"220","author":"Waddington","year":"1983","journal-title":"Science"},{"key":"10.1016\/0006-3223(93)90044-E_BIB285","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1176\/ajp.143.9.1162","article-title":"An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms","volume":"143","author":"Waddington","year":"1986","journal-title":"Am J Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB286","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpsyc.1987.01800220077011","article-title":"Cognitive dysfunction, negative symptoms and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality","volume":"44","author":"Waddington","year":"1987","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB287","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0165-1781(85)90124-6","article-title":"Cognitive impairment in tardive dyskinesia","volume":"16","author":"Wegner","year":"1985","journal-title":"Psychiatry Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB288","article-title":"A theory of the mammalian striatum","author":"Wickens","year":"1990"},{"key":"10.1016\/0006-3223(93)90044-E_BIB289","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF01245020","article-title":"Striatal dopamine in motor activation and reward-mediated learning: steps towards a unifying model","volume":"80","author":"Wickens","year":"1990","journal-title":"J Neural Transm [Gen Sect]"},{"key":"10.1016\/0006-3223(93)90044-E_BIB290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/syn.890080102","article-title":"Two dynamic models of striatal function under dopaminergic-cholinergic control: Stimulation and analysis of a model","volume":"8","author":"Wickens","year":"1991","journal-title":"Synapse"},{"key":"10.1016\/0006-3223(93)90044-E_BIB291","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0006-8993(89)90833-0","article-title":"Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain","volume":"487","author":"Wilmot","year":"1989","journal-title":"Brain Res"},{"key":"10.1016\/0006-3223(93)90044-E_BIB292","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/schbul\/9.2.187","article-title":"Is there a tardive dysmentia","volume":"9","author":"Wilson","year":"1983","journal-title":"Schizophr Bull"},{"key":"10.1016\/0006-3223(93)90044-E_BIB293","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00433729","article-title":"A depot neuroleptic withdrawal study: plasma concentrations of fluphenazine and flupenthixol and relapse frequency","volume":"78","author":"Wistedt","year":"1982","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/0006-3223(93)90044-E_BIB294","first-page":"1181","article-title":"The clinical association of tardive dyskinesia and drug-induced Parkinsonism","volume":"18","author":"Wolf","year":"1983","journal-title":"Biol Psychiatry"},{"key":"10.1016\/0006-3223(93)90044-E_BIB295","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF01249124","article-title":"Effect of a stereospecific D2-dopamine agonist on acetylcholine concentration in corpus striatum in rat brain","volume":"58","author":"Wong","year":"1983","journal-title":"J Neural Transm"},{"key":"10.1016\/0006-3223(93)90044-E_BIB296","first-page":"233","article-title":"Tardive dyskinesia and anticholinergic drugs. A critical review of the literature","volume":"14","author":"Yassa","year":"1988","journal-title":"Encephale"},{"key":"10.1016\/0006-3223(93)90044-E_BIB297","first-page":"441","article-title":"Depression as a predictor in the development of tardive dyskinesia","volume":"19","author":"Yassa","year":"1984","journal-title":"Biol Psychiatry"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:000632239390044E?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:000632239390044E?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T12:19:07Z","timestamp":1734005947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/000632239390044E"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,11]]},"references-count":297,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1993,11]]}},"alternative-id":["000632239390044E"],"URL":"https:\/\/doi.org\/10.1016\/0006-3223(93)90044-e","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[1993,11]]}}}